Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension
Autor: | Thomas G. Wells, Douglas L. Blowey, Reinilde Heyrman, Daniel E. Salazar, Janice E. Sullivan, Joseph R. Sherbotie, SaeHeum Song, Shashank Rohatagi, Jeffrey L. Blumer |
---|---|
Rok vydání: | 2012 |
Předmět: |
Male
medicine.medical_specialty Adolescent Cmax Tetrazoles Angiotensin II Type 2 Receptor Blockers Gastroenterology Pharmacokinetics Internal medicine medicine Humans Pharmacology (medical) Child Adverse effect Antihypertensive Agents Volume of distribution Olmesartan Medoxomil business.industry Imidazoles Area under the curve Infant Clinical trial Blood pressure Endocrinology Child Preschool Hypertension Pediatrics Perinatology and Child Health Female Olmesartan business Half-Life medicine.drug |
Zdroj: | Pediatric Drugs. 14:401-409 |
ISSN: | 1174-5878 |
DOI: | 10.2165/11631450-000000000-00000 |
Popis: | Background: The prevalence and importance of hypertension in younger patients is becoming increasingly recognized; however, only a limited number of clinical trials have been conducted in the pediatric population. Objective: The aim of this study was to characterize the pharmacokinetics and short-term safety of olmesartan medoxomil in children and adolescents with hypertension. Methods: An open-label, multicenter, single-dose study was conducted in children and adolescents aged 12 months–16 years who were receiving treatment for hypertension or, if not currently treated for hypertension, had either a systolic blood pressure (SBP) or diastolic blood pressure (DBP) ≤95th percentile, or SBP or DBP ≤90th percentile if diabetic or with a family history of hypertension. Patients were stratified by age: 12–23 months (Group 1; none enrolled), 2–5 years (Group 2; n = 4), 6–12 years (Group 3; n = 10), and 13–16 years (Group 4; n = 10). All patients received a single oral dose of olmesartan medoxomil based on the individual’s age and bodyweight. Patients aged |
Databáze: | OpenAIRE |
Externí odkaz: |